the integrated action of oestrogen receptor isoforms and sites with
TRANSCRIPT
107
The integrated action of oestrogen
receptor isoforms and sites withprogesterone receptor in the gonadotrope modulates LH secretion:evidence from tamoxifen-treated ovariectomized ratsJose C Garrido-Gracia*, Ana Gordon*, Carmina Bellido, Rafaela Aguilar, Inmaculada Barranco1,
Yolanda Millan1, Juana Martın de las Mulas1 and Jose E Sanchez-Criado
Departments of Cell Biology, Physiology and Immunology and 1Comparative Pathology, University of Cordoba, Cordoba, Spain
(Requests for offprints should be addressed to J E Sanchez-Criado who is now at Seccion de Fisiologıa, Facultad de Medicina, Avda. Menendez Pidal s/n, 14004
Cordoba, Spain; Email: [email protected])
*( J C Garrido-Gracia and A Gordon contributed equally to this work.)
Abstract
The specific role of each oestrogen receptor (ER) isoform
(a and b) and site (nucleus and plasma membrane) in LH
release was determined in ovariectomized (OVX) rats
injected over 6 days (days 15–20 after OVX) with a saturating
dose (3 mg/day) of tamoxifen (TX), a selective ERmodulator
with nuclear ERa agonist actions in the absence of oestrogen.
This pharmacological effect of TX was demonstrated by the
fact that it was blocked by the selective ERa antagonist
methyl-piperidino-pyrazole. Over the past 3 days of the 6-day
TX treatment, rats received either 25 mg/day oestradiol
benzoate (EB), 1.5 mg/day selective ERa agonist propyl-
pyrazole triol (PPT) and the selective ERb agonist
diarylpropionitrile (DPN), or a single 3 mg injection of the
antiprogestin onapristone (ZK299) administered on day 20.
Blood samples were taken to determine basal and
progesterone receptor (PR)-dependent LH-releasing
Journal of Endocrinology (2007) 193, 107–1190022–0795/07/0193–107 q 2007 Society for Endocrinology Printed in Great
hormone (LHRH)-stimulated LH secretion and to evaluate
LHRH self-priming, the property of LHRH that increases
gonadotrope responsiveness to itself. Blood LH concentration
was determined by RIA and gonadotrope PR expression by
immunohistochemistry. Results showed that i) EB and DPN
potentiated the negative feedback of TX on basal LH release;
ii) DPN reduced TX-induced PR expression; iii) EB and
PPT blocked TX-elicited LHRH self-priming and iv)
ZK299 reduced LHRH-stimulated LH secretion and blocked
LHRH self-priming. These observations suggest that
oestrogen action on LH secretion in the rat is exerted at the
classic ERa pool and that this action might be modulated by
both ERb and membrane ERa through their effects on PR
expression and action respectively.
Journal of Endocrinology (2007) 193, 107–119
Introduction
Luteinizing hormone (LH) secretion in the rat is dependent
on the activation of gonadotrope oestrogen receptors (ERs)
by ovarian-derived oestradiol-17b (E2; Fink 1988, 1995). Rat
gonadotropes express both isoforms of ER, the predominant
ERa (Lindzey et al. 2006) and ERb at nuclear level (Kuiper
et al. 1997, Mitchner et al. 1998, Vaillant et al. 2002,
Sanchez-Criado et al. 2005a). In addition, an ER which
appears to be the same protein as nuclear ERa is expressed at
the plasma membrane level (Bression et al. 1986, Razandi
et al. 1999, Toran-Allerand et al. 1999, Schmidt et al. 2000,
Kelly & Levin 2001, Simoncini & Genazzani 2003,
Toran-Allerand 2004, Levin 2005). Integration of E2 effects
at different ER pools in the gonadotrope (nuclear ERa and
ERb and membrane ERa) determines the cellular actions of
E2 on basal and preovulatory LH secretion and hence on
ovulation (Fink 1988, 2000). Since E2 activates the complete
ER orchestra in the gonadotrope, it is difficult to chart
separately the specific role of each ER pool on LH secretion
using either intact cyclic or ovariectomized (OVX) rats
treated with the cognate ligand. ERa and ERb isoform
knockout mice (Pelletier et al. 2003, Lindzey et al. 2006) are
not useful models for the study of ER isoforms interaction
either because one or the other ER isoform is lacking. The
discovery of ER subtype-selective ligands, such as the ERaagonist propylpyrazole triol (PPT; Stauffer et al. 2000), the
ERb agonist diarylpropionitrile (DPN; Meyers et al. 2001)
and the ERa-selective antagonist methyl-piperidino-pyrazole
(MPP; Sun et al. 2002, Harrington et al. 2003), affords useful
tools for dissecting the biology of ER subtypes at pituitary
level (Sanchez-Criado et al. 2004, 2006a) in OVX rats.
A ying–yang relationship between ERb and ERa on
LH secretion has been reported in 2-week OVX rats
treated with these ER-selective agonists (Sanchez-Criado
et al. 2004, 2006a).
DOI: 10.1677/JOE-06-0214Britain Online version via http://www.endocrinology-journals.org
J C GARRIDO-GRACIA, A GORDON and others . ER isoforms and sites modulate LH secretion108
Tamoxifen (TX), a type I oestrogen antagonist with
selective ER modulator (SERM) properties (McDonnell
1999, 2003, McDonnell et al. 2002, Smith & O’Malley 2004),
exhibits agonist activities in the gonadotrope of OVX rats.
These actions of TX include shrinkage of OVX-induced
hypertrophy, induction of progesterone receptor (PR)
mRNA and protein expression, and PR-dependent LH-
releasing hormone (LHRH) self-priming in vitro (Bellido et al.
2003). LHRH self-priming is a phenomenon in which the
magnitude of the LH response to the second of two equal
exposures of LHRH separated by an interval of 60 min is
significantly greater than the response to the first exposure to
LHRH (Fink 1988). Evidence derived from in vitro work
indicates that the agonist actions of TX in the rat gonadotrope
are exerted at the nuclear ERa level exclusively. Therefore,
incubated pituitaries from OVX rats injected over 3 days with
pharmacological doses of TX exhibit LHRH self-priming
(Sanchez-Criado et al. 2005b) and this agonistic effect of TX is
inhibited when E2 or the membrane-impermeable analogue
conjugated E2–BSA is added to the incubation medium.
Moreover, addition of the pure type II anti-oestrogen
ICI182 780 (Smith & O’Malley 2004) to the medium blocks
the rapid inhibitory action of E2 on TX-elicited LHRH
self-priming, whereas TX itself does not (Sanchez-Criado
et al. 2005b). One emerging explanation of these in vitro data is
that TX selectively binds nuclear ERa but not ERb(Tzuckerman et al. 1994, Bellido et al. 2003, Sanchez-Criado
et al. 2004, 2005a) and exhibits extremely low affinity for
membrane ERa in rat gonadotropes (Sanchez-Criado et al.
2005b). In addition, these data suggest that E2 inhibition of
TX-elicited LHRH self-priming is due to activation of the
plasma membrane ERa (Sanchez-Criado et al. 2005b, 2006b).
The present study was designed to ascertain whether the
in vitro inhibitory effects of both nuclear ERb-initiatedsignalling (Sanchez-Criado et al. 2004) and membrane ERa-initiated signalling (Sanchez-Criado et al. 2005b) upon the
LH secretory actions of the nuclear ERa-initiated signalling
were also operative in the whole animal. To this purpose,
three groups of in vivo experiments were conducted: the first,
to verify the effects of TX on LH secretion, pituitary PR
expression and LHRH self-priming in 2-week OVX rats; the
second, to evaluate the role of the different ER isoforms and
sites in LH release in gonadotropes with TX-activated nuclear
ERa using the cognate ligand E2 and the selective ERa and
ERb agonists PPT and DPN respectively and the third to
verify that TX acts through ERa by studying the effects of the
selective ERa antagonist MPP.
Materials and Methods
Animals, general conditions and surgery
Adult female Wistar rats weighing 190–210 g were used. Rats
were housed under a 14 h light:10 h darkness cycle (light on
at 0500 h) and 22G2 8C room temperature, with ad libitum
Journal of Endocrinology (2007) 193, 107–119
access to rat chow and tap water available ad libitum. Rats were
bilaterally OVX under ether anaesthesia at random stages of
the oestrous cycle and assigned to experimental groups
14 days later. At the time indicated in each experiment, a
right atrial cannula was implanted using a previously
described procedure (Harms & Ojeda 1974, Sanchez-Criado
et al. 1993), and rats received an i.v. injection of 20 IU
heparin/250 ml saline. At 0900 h (time 0) the following day,
the distal ends of the cannulae were attached to extension
tubing (P50; Adams, Parsippany, NJ, USA) to permit blood
sampling and LHRH administration. Rats were given an i.v.
bolus of 25 ng LHRH, and a second one 60 min later. Blood
samples (250 ml each) were taken at 0, 15, 60, 75 and 120 min.
At the end of the experiments, anterior pituitaries were
removed and dissected out for the determination of protein
and LH contents. On day 18 (experiment 1) and day 21
(experiments 2, 3, 4 and 5), vaginal smears were taken. All
experimental protocols were approved by the Ethical
Committee of the University of Cordoba, and experiments
were performed in accordance with the rules on laboratory
animal care and with international law on animal
experimentation.
Drugs and treatments
TX (Sigma) was injected at pharmacological/saturating doses
of 3 mg/day (Sanchez-Criado et al. 2004, 2005b, 2006b). The
selective ERa and ERb agonists PPT and DPN respectively
(Tocris Cookson Ltd, Avonmouth, UK; Stauffer et al. 2000,
Meyers et al. 2001) were injected at doses of 1.5 mg/day
(Sanchez-Criado et al. 2004). PPT has a 400-fold preference
for ERa and does not activate ERb (Stauffer et al. 2000).
DPN has a 70-fold higher binding affinity for ERb than for
ERa (Meyers et al. 2001). Oestradiol benzoate (EB; Sigma)
was injected at the pharmacological dose of 25 mg/day. Thepotent ERa-selective antagonist methyl-piperidino-pyrazole
(MPP; Tocris) was dissolved in DMSA/olive oil (1/14, v/v)
and injected at a dose of 1 mg/day. This compound displays
220-fold more affinity for ERa than for ERb (Sun et al. 2002,
Harrington et al. 2003). The PR antagonist onapristone
(ZK299; Schering, Berlin, Germany; Neef et al. 1984, Bellido
et al. 1999) was injected at a dose of 3 mg. All ER ligands and
ZK299 were given subcutaneously in 0.2 ml oil (Table 1).
Synthetic LHRH (Peninsula Laboratory, Inc., Merseyside,
UK) was dissolved in saline at a concentration of 125 ng/ml,
and 0.2 ml of this solution was injected intravenously. The
saturating doses of steroid receptor ligands used in the present
experiments were based on previously published studies
(Table 1).
Experiment 1: effect of TX on LH secretion, PR expression andLHRH self-priming in OVX rats
Rats were injected either with TX or with oil vehicle and EB
(negative and positive control groups respectively) on days
15–17 after OVX. Less than 0.4 ml blood was drawn by direct
www.endocrinology-journals.org
Table 1 List of steroid receptor ligands used indicating their action and relevant references
Action
nERa nERb mERa nPR References
NameTamoxifen (TX) C Tzukerman et al. (1994) and
Sanchez-Criado et al. (2005b)Oestradiol benzoate (EB) C C C Sanchez-Criado et al. (2004, 2006b)Propylpyrazole triol (PPT) C C Stauffer et al. (2000) and
Sanchez-Criado et al. (2004)Diarylpropionitrile (DPN) C Meyers et al. (2001) and
Sanchez-Criado et al. (2004)Methyl-piperidino-pyrazole (MPP) K K Sun et al. (2002) and Harrington et al.
(2003)Onapristone (ZK299) K Neef et al. (1984) and Bellido et al.
(1999)
nERa, nuclear oestrogen receptor a; nERb, nuclear oestrogen receptor b; mERa, membrane oestrogen receptor a; nPR, nuclear progesterone receptor;C, activation; K, blockade.
ER isoforms and sites modulate LH secretion . J C GARRIDO-GRACIA, A GORDON and others 109
left jugular venipuncture under light ether anaesthesia at
0900 h on days 15, 16 and 17. On the afternoon of day 17,
rats were implanted with atrial cannulae. Pituitary LH
secretory response to LHRH was studied on day 18.
Pituitaries from similarly treated rats (four rats/group) were
processed for PR expression on day 18 after OVX. Serum and
plasma samples were stored frozen until the LH RIAwas run.
Experiment 2: effects of EB, PPTand DPN on LH secretion andLHRH self-priming in TX-injected OVX rats
Ratswere injectedwithTX (control group) on days 15–20 after
OVX. Over the past 3 days (days 18–20 after OVX) of TX
treatment, ratswere additionally injectedwithEB, PPTorDPN.
Less than 0.4 ml blood was taken by jugular venipuncture at
0900 h on days 18–20. On the afternoon of day 20, rats were
implanted with atrial cannulae. The pituitary LH secretory
response to LHRH was studied on day 21. Serum and plasma
samples were stored frozen until the LH RIAwas run.
Experiment 3: effects of EB, PPTand DPN on PR expression inTX-injected OVX rats
Rats were injected with TX (control group) on days 15–20
after OVX. Over the past 3 days (days 18–20 after OVX) of
TX treatment, rats were additionally injected with EB, PPTor
DPN. At 0900 h on day 21 after OVX, four rats in each of the
four groups (TX, TXCEB, TXCPPTand TXCDPN) were
decapitated and their anterior pituitaries dissected out and
processed for PR immunoreactivity.
Experiment 4: effects of ZK299 on LH secretion and LHRHself-priming elicited by TX
The action of ligand-independent activation of PR on LH
secretion was evaluated in 6-day TX-injected OVX rats given
www.endocrinology-journals.org
a single injection of 3 mg ZK299 at 0900 h on day 20.
Basal and LHRH-stimulated LH secretion and LHRH
self-priming were studied on day 21. Plasma samples were
stored frozen until the LH RIA was run.
Experiment 5: effects of MPP on LH secretion, PR expressionand LHRH self-priming in TX-injected OVX rats
Rats were injected daily from days 15 to 20 after OVX with
MPP, with or without TX injections on days 18–20 after OVX.
Control groups consisted of OVX rats injected with 0.2 ml oil
from days 15 to 20 and TX alone from days 18 to 20. Less than
0.4 ml blood was taken by jugular venipuncture at 0900 h on
days 15, 18, 19 and 20. On the afternoon of day 20, rats were
implanted with atrial cannulae. On day 21, the pituitary LH
secretory response to LHRH was studied. In addition,
pituitaries from similarly treated OVX rats (three rats/group)
were processed for PR immunoreactivity on day 21. Serum and
plasma samples were stored frozen until the LH RIAwas run.
Pituitary LH content determination
At the end of each experiment, either on day 18 or 21,
anterior pituitaries were removed and homogenized in 1 ml
RIA buffer and subjected to ultrasonic treatment. Samples
were centrifuged at 2800 g for 10 min and the supernatants
frozen at K20 8C until assayed by LH RIA. Pituitary LH
content was expressed as mg/mg protein. Pituitary protein
content was determined by the micro-turbidimetric method
using benzethonium chloride in alkali (Iwata & Nishikaze
1979). The sensitivity of the method was 40 mg/ml.
RIA of LH
Serumor plasma LHconcentrationsweremeasured in duplicate
by RIA using a double-antibody method with a kit supplied by
Journal of Endocrinology (2007) 193, 107–119
J C GARRIDO-GRACIA, A GORDON and others . ER isoforms and sites modulate LH secretion110
NIH (Bethesda, MD, USA) and a previously described
microassay method (Sanchez-Criado et al. 1993, Bellido et al.
1999). Rat LH-I-9 was labelled with 125I by the chloramine-T
method (Greenwood et al. 1963). The intra- and inter-assay
coefficients of variation were 8 and 9% respectively. Assay
sensitivity was 3.5 pg/tube. LH was expressed as ng/ml of the
reference preparation LH-rat-RP-3.
LHRH self-priming
The peak pituitary response of LH occurs after 15-min
administration of LHRH pulse (Sanchez-Criado et al. 2005b).
In the present experiments, LHRH self-priming was
evaluated as the percentage increase in LH secretion to the
second LHRH pulse (primed pituitary response) with respect
to the first LHRH pulse (LHRH-stimulated LH secretion or
unprimed pituitary response).
Immunohistochemistry of pituitary PR
The immunohistochemical study was performed on dewaxed
and rehydrated 3 mm thick tissue sections of formalin-fixed,
paraffin-embedded tissue samples. The commercial mouse
monoclonal anti-human PR antibody clone PR10A9, raised
against the recombinant hormone-binding domain of human
PR located on the C-terminal domain of PR (Immunotech,
Marseille, France), diluted in the ratio of 1:15 000, and the
avidin–biotin peroxidase complex (ABC) technique (Vector,
Burlingame, CA, USA) were used as described previously
(Sanchez-Criado et al. 2004). Tissue sections from similarly
processed samples of rat uterus and human breast carcinoma
were used as positive controls. The specificity of the PR
antibody was shown by the lack of staining after pre-
incubation of tissue sections of rat uterus and pituitaries from
OVX rats treated with EB with 10K9, 10K7 and 10K5 M of
the cognate ligand for 1 h at 37 8C. Substitution of the specific
primary antibody by mouse ascitic fluid at the same dilution as
the specific primary antibody in tissue sections of the cases
under study was used as negative control. Several dilutions of
the PR10A9 monoclonal antibody were tested and the
optimal dilution was established at 1:15 000, because it gave
the highest intensity of nuclear staining with the lowest
background staining in pituitary and uterus (Sanchez-Criado
et al. 2004). Nuclear counterstaining was performed with
Mayer’s haematoxylin in all cases. The amount of cells
immunoreactive to PR antibody was expressed as the number
of positive nuclei counted in five fields at a magnification of
40! (about 240 pituitary cells/field) in each pituitary. All
immunoreactive cells were considered to be gonadotropes
because they are the only pituitary cells expressing PR (Fox
et al. 1990, Sanchez-Criado et al. 2005a).
Figure 1 Serum LH concentrations in ovariectomized (OVX) ratsinjected on days 15, 16 and 17 after OVX with 0.2 ml oil, 25 mgoestradiol benzoate (EB) or 3 mg tamoxifen (TX). Values aremeansGS.E.M. of ten rats. aP!0.05 versus oil-injected rats. ANOVAand Student–Newman–Keuls multiple range test.
Statistical analysis
Statistical analysis was performed by ANOVA to check
for significant differences among groups. When significant
Journal of Endocrinology (2007) 193, 107–119
differences existed, it was followed by the Student–Newman–
Keuls multiple range test for inter-group comparison.
Significance was considered at the 0.05 level.
Results
Effects of treatment with different ER ligands on vaginal smears inOVX rats
OVX rats treated with the ER agonists EB, TX and TX plus
EB, PPT, DPN or TX plus the PR antagonist ZK299 showed
either nucleated or fully cornified epithelial cells in vaginal
smears. In contrast, OVX rats injected with oil displayed
vaginal smears predominantly infiltrated by leukocytes. The
ERa antagonist MPP, either alone or in combination with
TX, behaved as an ER agonist because it also induced
cornification of vaginal smears.
Effect of TX on LH secretion, gonadotrope PR expression andLHRH self-priming in OVX rats
Treatment of 2-week OVX rats with TX over 3 days had
similar (though less pronounced) effects to treatment with the
cognate ligand EB over the same period of time. Therefore,
TX reduced both basal serum/plasma LH concentration
(Figs 1 and 2) only on days 17 and 18 and pituitary LH
content (Table 2) on day 18 after OVX. In addition,
TX-induced LHRH self-priming, as the magnitude of the
www.endocrinology-journals.org
Figure 2 Plasma LH concentrations in ovariectomized (OVX) ratsinjected on days 15, 16 and 17 after OVX with 0.2 ml oil, 25 mgoestradiol benzoate (EB) or 3 mg tamoxifen (TX). At 0900 h on day 18(time 0), rats received an i.v. bolus of 25 ng LHRH (first arrow), anda second one 60 min later (second arrow). Blood samples (250 mleach) were taken at 0, 15, 60, 75 and 120 min through a right atrialcannula implanted on the afternoon of day 17 after OVX. Values aremeansGS.E.M. of eight to ten rats. aP!0.05 versus LH values 15 minafter the first challenge with LHRH. bP!0.05 versus oil-injected rats.cP!0.05 versus LH concentration (time 0) in oil-injected rats.ANOVA and Student–Newman–Keuls multiple range test.
Table 2 Luteinizing hormone (LH)-releasing hormone (LHRH) self-priming and LH pituitary content (mg/mg protein) in ovariectomized(OVX) rats injected daily with 0.2 ml oil (oil-3), 25 mg oestradiolbenzoate (EB-3) and 3 mg tamoxifen (TX-3) over 3 days (days 15–17after OVX), or with 3 mg TX alone (TX-6) over 6 days (days 15–20 afterOVX)or incombinationwith25 mgEB (TX-6CEB), 1.5 mgPPT (TX-6CPPT) or 1.5 mg DPN (TX-6CDPN) injected ondays 18–20after OVX.Asingle 3 mg ZK299 injection was given on day 20 to TX-treated rats (TX-6CZK299). See legend of Figs 2 and 4 for additional details oftreatments. LHRH self-priming was expressed as the percentageincrease of peak LH response to a second 25 ng LHRH pulse (primedpituitary response) with respect to the LH peak response to the first25 ng LHRH pulse (unprimed pituitary response) after 1 h. Values aremeansGS.E.M. of eight to ten determinations
LHRH self-priming LH (mg/mg)
GroupsOil-3 101.9G8.9 54.6G3.1EB-3 152.4G13.7* 43.3G3.9*TX-3 146.4G7.7* 39.7G3.6*TX-6 143.7G3.4* 35.2G2.4*TX-6CEB 100.8G11.0 38.7G3.9*TX-6CPPT 103.7G10.6 38.0G4.2*TX-6CDPN 150.5G11.6* 37.7G4.3*TX-6CZK299 104.9G8.9 31.6G2.3*
*P!0.05 versus oil-injected rats. ANOVA and Student–Newman–Keulsmultiple range test.
ER isoforms and sites modulate LH secretion . J C GARRIDO-GRACIA, A GORDON and others 111
www.endocrinology-journals.org
LH response to the second LHRH challenge, was signi-
ficantly increased with respect to the LH peak response to the
first LHRH pulse (Fig. 2; Table 2). A similar magnitude of
LHRH self-priming was also observed in OVX rats treated
with EB (positive control group), but not in OVX rats
injected with oil vehicle (negative control group; Fig. 2;
Table 2). However, TX did not sensitize the pituitary to
LHRH, which contrasted with the pituitary sensitizing action
of EB to LHRH (Fig. 2).
Effect of EB, PPTand DPN upon the inhibitory effect of TX onbasal LH secretion and on TX-elicited LHRH self-priming inOVX rats
The inhibitory effect of a 3-day TX treatment on serum LH
concentration and pituitary LH content in OVX rats was
further enhanced after 6-day treatment of OVX rats with TX
(Fig. 3; Table 2). This dose-related inhibitory effect of TX on
basal LH levels was potentiated by the simultaneous
administration of either EB or the selective ERb agonist
DPN on days 18–20 after OVX (Figs 3 and 4). However,
administration of the selective ERa agonist PPT did not
Figure 3 Serum LH concentrations on days 18, 19 and 20 inovariectomized (OVX) rats injected daily on days 15–20 after OVXwith 3 mg tamoxifen (TX) alone, or in combination with 25 mgoestradiol benzoate (TXCEB), 1.5 mg PPT (TXCPPT) or 1.5 mgDPN (TXCDPN) injected over the past 3 days (days 18–20 afterOVX) of TX treatment. Values are meansGS.E.M. of ten rats.aP!0.05 versus TX-injected rats. ANOVA and Student–Newman–Keuls multiple range test.
Journal of Endocrinology (2007) 193, 107–119
Figure 4 Plasma LH concentrations in ovariectomized (OVX) rats injected on days 15–20 after OVX with 3 mg tamoxifen (TX) alone,or combined with 25 mg oestradiol benzoate (TXCEB), 1.5 mg PPT (TXCPPT) or 1.5 mg DPN (TXCDPN) on days 18, 19 and 20 after OVX.A single 3 mg ZK299 injection was given on day 20 to TX-treated rats (TXCZK). At 0900 h on day 21 (time 0), rats received an i.v. bolusof 25 ng LHRH (first arrow), and a second challenge 60 min later (second arrow). Blood samples (250 ml each) were taken at 0, 15, 60, 75 and120 min through a right atrial cannula implanted on the afternoon of day 20 after OVX. Values are meansGS.E.M. of eight to ten rats. aP!0.05versus LH levels 15 min after the first LHRH challenge. bP!0.05 versus LHRH-stimulated LH secretion in TX-injected rats. cP!0.05versus LH concentration (time 0) in TX-treated rats. ANOVA and Student–Newman–Keuls multiple range test.
J C GARRIDO-GRACIA, A GORDON and others . ER isoforms and sites modulate LH secretion112
potentiate this inhibitory effect of TX (Figs 3 and 4). No effect
on pituitary LH content was noted after treatment with EB,
PPTor DPN (Table 2). TX treatment of OVX rats over 6 days
(days 15–20 after OVX) induced LHRH self-priming which
was blocked by both EB and PPT, but not by DPN treatments
over 3 days (days 18–20 after OVX, Fig. 4; Table 2).
Effect of ZK299 on LH secretion and LHRH self-priming inTX treated in OVX rats
The blockade of PR activity with ZK299 given on day 20 to
6-day TX-treated OVX rats reduced basal and LHRH-
stimulated LH secretion and blocked LHRH self-priming on
day 21 (Fig. 4). The antiprogestagen had no effect on pituitary
LH content (Table 2).
Effect of EB, PPT and DPN upon TX-induced PR expressionin OVX rats
Immunoreactive products to PR antibody were detected in
the nuclei of gonadotropes in pituitaries from OVX rats
Journal of Endocrinology (2007) 193, 107–119
treated over 3 or 6 days with TX (Fig. 5). PR expression was
higher after 6 days of TX treatment. In these rats, PR
immunoreactivity was found in either hypertrophied or
shrunken gonadotropes (Fig. 5; upper panel). In contrast, oil-
injected OVX rats exhibited hypertrophied gonadotropes
lacking PR expression. The number of PR immunoreactive
cells observed in pituitaries from 6-day TX-treated OVX rats
was reduced by co-administration of the selective ERbagonist DPN over the past 3 days of TX treatment (Fig. 5;
lower panel), while the selective ERa agonist PPT and the
cognate ligand EB had no significative effect on the number of
PR immunoreactive cells (Fig. 5; lower panel).
Effect of MPP on TX agonist actions in OVX rats
The agonist actions of TX in OVX rats injected on days 18–20
after OVX included: reduction of basal LH serum/plasma
concentration (Fig. 6) and pituitary LH content (Table 3),
induction of LHRH self-priming (Fig. 7; Table 3) and PR
expression on day 21 (Fig. 8). MPP treatment blocked the
TX-elicited LHRH self-priming (Fig. 7; Table 3) and reduced
www.endocrinology-journals.org
ER isoforms and sites modulate LH secretion . J C GARRIDO-GRACIA, A GORDON and others 113
www.endocrinology-journals.org Journal of Endocrinology (2007) 193, 107–119
Table 3 LHRH self-priming and LH pituitary content (mg/mgprotein) in OVX rats injected over 6 days (days 15–20 after OVX)with 0.2 ml oil or 1.0 mg selective ERa antagonist MPP alone, orcombined with 3 mg TX on days 18–20 after OVX
LHRH self-priming LH (mg/mg)
GroupsOil 92.3G9.8 49.8G6.1MPP 107.8G11.1 36.1G3.2*TX 166.7G14.8* 30.6G4.2*MPPCTX 113.8G12.4 32.2G2.4*
See legend of Fig. 7 for additional details of treatments. LHRH self-priming wasexpressed as the percentage increase of peak LH response to a second 25 ngLHRH pulse (primed pituitary response) with respect to the LH peak responseto the first 25 ng LHRH pulse (unprimed pituitary response) after 1 h. Valuesare meansGS.E.M. of seven to eight determinations. *P!0.05 versusoil-injected rats. ANOVA and Student–Newman–Keuls multiple range test.
Figure 6 Serum LH concentrations on days 15, 18, 19 and 20 inovariectomized (OVX) rats injected on days 15–20 after OVX with0.2 ml oil or 1.0 mg MPP alone or in combination with 3 mg TX ondays 18–20. Values are meansGS.E.M. of eight rats. Serum LHconcentration on day 15 after OVX is the mean of 32 rats. *P!0.05versus oil-injected rats. ANOVA and Student–Newman–Keulsmultiple range test.
J C GARRIDO-GRACIA, A GORDON and others . ER isoforms and sites modulate LH secretion114
the TX-induced PR expression (Fig. 8). On the contrary, MPP
alone injected daily from days 15 to 20 after OVX reduced basal
LH serumconcentration andpituitary LHcontent (Figs 6 and 7;
Table 3), a negative feedback on LH secretion similar to the
agonist effect of TX (Figs 1–3) in OVX rats.
Discussion
The results of the present experiments indicate that TX has
ERa agonist actions in the gonadotrope of OVX rats.
Assuming that a 6-day TX treatment also prevented the action
Figure 5 Immunohistochemical progesterone receptor (PR) expression inshows representative examples of PR expression in OVX rats injected ooestradiol benzoate (EB-3) or 3 mg tamoxifen (TX-3). An example of thTX-treated rats is also shown (TX-6). Hypertrophied gonadotropes withgonadotropes expressing PR (black arrows) are shown. Avidin–biotin perwith Mayer’s haematoxylin, !40. The lower panel represents the numbeinjected daily over 3 days with 0.2 ml oil (oil-3), 25 mg EB (EB-3) or 3 mgalone (TX-6) or in combination, over the past 3-day TX treatment, withDPN (TX-6CDPN) and studied on day 21 after OVX. Values are meansGOVX rats. bP!0.05 versus TX-6. cP!0.05 versus TX-3. ANOVA and St
Journal of Endocrinology (2007) 193, 107–119
of other ER ligands at the nuclear ERa level (Sanchez-
Criado et al. 2005b), results show, in addition, that the
bimodal components of gonadotrope LH release with
TX-activated nuclear ERa are differentially affected by the
simultaneous activation of ER isoforms and sites as follows:
1) The inhibitory effect of TX on PR-independent basal LH
secretion was potentiated by activation of ERb with DPN
and EB but not by activation of membrane ERa with PPT.
2) The PR-dependent LH secretory surge elicited through
nuclear ERa was inhibited by activation of ERb with DPN
and EB, and membrane ERa with PPTand EB through their
effects on PR expression and action respectively.
The known in vitro agonist actions of TX on LH release
have been confirmed in vivo using long-term OVX rats. The
2-week OVX rat model was used because treatment of these
rats over 3 days with EB mimicks the endocrine events of pro-
oestrus through augmentation of the LHRH-releasing
pathway, induction of PR expression and induction of
PR-dependent LHRH self-priming (Bellido et al. 2003,
Sanchez-Criado et al. 2004) culminating in an ovulatory LH
surge (Legan & Tsai 2003). The administration of pharma-
cological/saturating dose of TX to these OVX rats decreased
both serum and pituitary LH levels in a negative feedback
manner, induced upregulation of PR expression in the
gonadotrope, and elicited LHRH self-priming. In addition, it
has also been confirmed in vivo that these agonist actions of
TX in the gonadotrope of OVX rats are due to the activation
the pituitary of 15-day ovariectomized (OVX) rats. The upper panelver 3 days (days 15–17 after OVX) with 0.2 ml oil (oil-3), 25 mge PR expression in the pituitaries of 6-day (days 15–20 after OVX)(white arrows) or without (arrowhead) PR expression and shrunkenoxidase complex immunohistochemical technique, counterstainingr of anterior pituitary cells expressing PR in pituitaries from OVX ratsTX (TX-3) and studied on day 18 after OVX, or over 6 days with TX
25 mg oestradiol benzoate (TX-6CEB), 1.5 mg PPT (TX-6CPPT) orS.E.M. of 20 fields (five fields!four rats). aP!0.05 versus oil-injectedudent–Newman–Keuls multiple range test.
www.endocrinology-journals.org
Figure 7 Plasma LH concentrations on day 21 after ovariectomized (OVX) rats injected on days 15–20 after OVX with 0.2 ml oil or 1.0 mgMPPalone or with 3 mg TX on days 18–20. At 0900 h on day 21 (time 0), rats received an i.v. bolus of 25 ng LHRH (first arrow), and a secondchallenge 60 min later (second arrow). Blood samples (250 ml each) were taken at 0, 15, 60, 75 and 120 min through a right atrial cannulaimplanted on the afternoon of day 20 after OVX. Values are meansGS.E.M. of seven to eight rats. aP!0.05 versus LH levels after the first LHRHchallenge at time 0 in TX-injected OVX rats. bP!0.05 versus oil-injected rats. ANOVA and Student–Newman–Keuls multiple range test.
ER isoforms and sites modulate LH secretion . J C GARRIDO-GRACIA, A GORDON and others 115
of nuclear ERa (Sanchez-Criado et al. 2005b). The
administration of the ERa-selective antagonist MPP to
TX-treated OVX rats both reduced TX-induced PR
expression to a minimum and abolished TX-elicited
LHRH self-priming. However, MPP did not behave as an
ERa antagonist exclusively. This is because MPP reduced
basal LH secretion and induced vaginal smears cornification
in the absence of TX treatment. Taken together, these
findings indicate that MPP behaved as a SERM.
The first and longer phase of LH release in the gonadotrope
is PR-independent basal LH secretion. For most of the
reproductive life of females, LH levels are kept within a
relatively low range by the PR-independent (Chappell et al.
1999) negative feedback of moderate levels of oestrogen (Fink
1988). Whereas activation of ERa with the selective agonist
www.endocrinology-journals.org
PPTreduces LH secretion in OVX rats (Sanchez-Criado et al.
2004), PPT failed to reduce serum LH levels when
administered to TX-treated OVX rats, indicating a probable
competition of the selective ERa agonist for the same ER
isoform in which TX acts. In addition, the present data
showed that: i) activation of ERb either with DPN or EB
potentiated the TX-induced reduction of serum LH levels in
OVX rats; ii) activation of both ER isoforms with EB was
more effective in reducing serum LH levels than activation of
nuclear ERa alone with TX and iii) the potent selective ERaantagonist MPP administered alone reduced PR-independent
LH secretion in an agonistic manner. These findings
indicate that the negative feedback of oestrogen on LH
secretion is a genomic ERa effect potentiated by activation
of ERb.
Journal of Endocrinology (2007) 193, 107–119
Figure 8 Immunohistochemical progesterone receptor (PR)expression in the pituitary of 15-day ovariectomized (OVX) rats. Theupper panel shows representative examples of PR expression inOVX rats injected over 6 days (days 15–20 after OVX) with 0.2 mloil or 1.0 mg selective ERa antagonist MPPalone, or combined with3 mg tamoxifen (TX) on days 18–20 after OVX. Hypertrophiedgonadotropes with (white arrows) and without (arrowhead) PR andshrunken gonadotropes expressing PR (black arrows) are shown.The lower panel represents the number of anterior pituitary cellsexpressing PR in pituitaries from OVX rats injected with oil, MPP, TXor MPPCTX and studied on day 21 after OVX. Values are meansGS.E.M. of 15 fields (five fields!three rats). aP!0.05 versus oil-injected OVX rats. bP!0.05 versus TX-injected OVX rats. Seelegend of Fig. 5 for additional technical and morphological details.
J C GARRIDO-GRACIA, A GORDON and others . ER isoforms and sites modulate LH secretion116
Journal of Endocrinology (2007) 193, 107–119
The expression of PR in the gonadotrope is an oestrogen
effect of both E2 and TX which occurs simultaneously with
their negative feedback on LH secretion (Sanchez-Criado
et al. 2004, 2006a). Gonadotrope PR expression gives rise to a
complex phase: the PR-dependent LH surge elicited by an
acute rise in E2 levels (Chappell et al. 1999). The LH surge has
two components: 1) LHRH-stimulated LH secretion and 2)
the LHRH self-priming. The former occurs in an oestrogen
positive feedback manner, in which oestrogen increases
pituitary responsiveness to the releasing effects of LHRH
(Arimura & Schally 1971, Schuiling et al. 1999, Schwartz
2000) through activation of the nuclear ERa isoform
(Sanchez-Criado et al. 2004, Lindzey et al. 2006). Since
TX, neither in vitro (Sanchez-Criado et al. 2002, 2004) nor
in vivo (present results), sensitized the pituitary to the releasing
effects of LHRH, the role of the different ER pools in
LHRH-stimulated LH secretion cannot be directly
determined from the present experiments. However, two
findings strongly suggest that PR actions are involved
(Chappell et al. 1999, Sanchez-Criado et al. 2004) in ER
actions in TX-treated rats: i) activation of ERb with DPN
halved pituitary PR expression levels and ii) the complete
blockade of PR action with ZK299 decreased LHRH-
stimulated LH secretion. The absence of a significant effect of
activation of ERb with EB on TX-induced PR levels might
be due to PR synthesis-related gene transcription from the
large cytosolic pool of ER as EB activates the whole ER
orchestra (Levin 2001, 2005). This may have resulted in
overlapping ER functions in TX-treated OVX rats. Further-
more, it is also possible that the cognate ligand could have
partially displaced TX from nuclear ERa because of the
pharmacological doses used. Overall, the accumulated
evidence from presented and previous data (Sanchez-Criado
et al. 2004, 2006a) suggests that activation of ERb reduces
the efficiency of LHRH in stimulating LH release in
TX-treated rats.
The second component of PR-dependent LH surge
is oestrogen-dependent LHRH self-priming (Waring &
Turgeon 1980, 1992), the property of LHRH that increases
gonadotrope responsiveness to itself. It depends both on
de novo synthesis of priming proteins (Turgeon & Waring
1991) and on the oestrogen-induced upregulation of PR in
gonadotropes (Turgeon & Waring 1994). PR is a neuro-
endocrine integrator keystone in the LHRH self-priming
process (Turgeon & Waring 1991, 1994, Levine et al. 2001).
It has been observed that LHRH self-priming is a convincing
nuclear ERa-mediated effect (Sanchez-Criado et al. 2004).
Activation of ERa with PPT induces PR expression and
elicits LHRH self-priming in OVX rats, whereas activation of
ERb alone with DPN induces PR expression not followed by
LHRH self-priming (Sanchez-Criado et al. 2004). The fact
that administration of TX to OVX rats induced both PR
expression and LHRH self-priming further supports a nuclear
ERa agonist action of TX at the rat pituitary level. Although
DPN reduced PR expression levels in TX-treated rats, and
LHRH self-priming depends on PR, the remnant PR, about
www.endocrinology-journals.org
Figure 9 Proposed integrated action of oestrogen receptor (ER) isoforms and sites withprogesterone receptor (PR) in the rat gonadotrope. E2, oestradiol-17b; P4, progesterone;mERa, plasma membrane ERa; nERa, nuclear ERa; nERb, nuclear ERb; LHRH, luteinizinghormone-releasing hormone; LH, luteinizing hormone; GnSI/AF, putative non-steroidalovarian gonadotrophin surge inhibiting/attenuating factor (Byrne et al. 1996); mis,membrane-initiated signalling; nis, nucleus-initiated signalling. 1. Activation of nERa bygranulosa cells E2 transcriptionally induces PR expression and the simultaneous activation ofERb modulates this action in a ying–yang mode. 2. The E2-dependent LHRH surge activatesPR in the absence of P4 in a ligand-independent manner. 3. P4 from luteinized granulosa cellsin response to LH phosphorylates and activates PR. 4. Ovarian E2 activation of mERastimulates intracellular phosphatases (Sanchez-Criado et al. 2006b), which results in non-transcriptional reduction of PR phosphorylation and decreased LHRH self-priming. 5. Theputative ovarian GnSI/AF decreases PR action through membrane-initiated signalling.Broken arrow indicates that PR activation is not the only cause involved in elicitingoestradiol-augmenting and LHRH self-priming factors.
ER isoforms and sites modulate LH secretion . J C GARRIDO-GRACIA, A GORDON and others 117
www.endocrinology-journals.org Journal of Endocrinology (2007) 193, 107–119
J C GARRIDO-GRACIA, A GORDON and others . ER isoforms and sites modulate LH secretion118
one-half of that found in TX-treated rats, may have been
enough to elicit LHRH self-priming once activated in a
ligand-independent manner (Levine 1997, Blaustein 2004).
This finding rules out the possibility of an ERb involvement
in EB inhibition of TX-induced LHRH self-priming. The
finding that treatment with either EB or PPT, but not DPN,
blocked TX-elicited LHRH self-priming sharply contrasted
with the facilitatory action of both ERa agonists on LHRH
self-priming in the absence of TX treatment (Sanchez-Criado
et al. 2004). Moreover, ZK299 similarly annulled TX-elicited
LHRH self-priming. These facts suggest that both EB
and PPT acted on an ERa pool different from that bound
to TX resulting in inhibition of PR action (Sanchez-Criado
et al. 2006b).
On the basis of both the present in vivo and the previous
in vitro results (Sanchez-Criado et al. 2004, 2005a,b, 2006a,b),
one might hypothesize the following mechanism of E2 action
on the complete ER orchestra upon LH secretion in the
gonadotrope of the rat: 1) the PR-independent negative
oestrogen feedback may be exerted at the nuclear ERa and
ERb complementarily; 2) the positive feedback of oestrogen
on LHRH-stimulated LH secretion, a nuclear ERa action,
may be modulated by the inhibitory action of ERb on PR
expression (Fig. 9) and 3) the oestrogen-dependent LHRH
self-priming may be a nuclear ERa action modulated by
surface ERa-initiated signalling inhibition of PR action
(Fig. 9).
Acknowledgements
This study was subsidized by grants (BFU2005-01443 and
AGL2006-09016/GAN) from the DGICYT (Spain). The
authors are grateful to the National Hormone and Pituitary
Program (Baltimore, MD, USA) for the LH RIA kit and to
Teresa Recio for technical assistance. The authors declare that
there is no conflict of interest that would prejudice the
impartiality of this scientific work.
References
Arimura A & Schally AV 1971 Augmentation of pituitary responsiveness to
LH-releasing hormone (LH-RH) by estrogen. Proceedings of the Society for
Experimental Biology and Medicine 136 290–293.
Bellido C, Gonzalez D, Aguilar R & Sanchez-Criado JE 1999 Antiprogestins
RU486 and ZK299 suppress basal and LHRH-stimulated FSH and
LH secretion at pituitary level in the rat in an oestrous cycle stage-
dependendent manner. Journal of Endocrinology 163 79–85.
Bellido C, Martın de las Mulas J, Tena-Sempere M, Aguilar R, Alonso R &
Sanchez-Criado JE 2003 Tamoxifen induces gonadotropin-releasing
hormone self-priming through an estrogen-dependent progesterone receptor
expression in the gonadotrope of the rat. Neuroendocrinology 77 425–435.
Bellido C, Aguilar R, Alonso R, Garrido-Gracia JC & Sanchez-Criado JE
2005 Estradiol 17b blocks the estrogenic effect of tamoxifen on LH and
PRL secretion in the rat. Journal of Physiology and Biochemistry 61 149–150.
Blaustein JD 2004 Minireview: neuronal steroid hormone receptors: they’re
not just for hormones anymore. Endocrinology 145 1075–1081.
Journal of Endocrinology (2007) 193, 107–119
Bression D, Michard M, Le Dafniet M, Pagesy P & Peillon F 1986 Evidence
for a specific estradiol binding site on rat pituitary membranes. Endocrinology
119 1048–1051.
Byrne B, FowlerPA&TempletonA1996Role of progesterone and nonsteroidal
ovarian factors in regulating gonadotropin-releasing hormone self-priming
in vitro. Journal of Clinical Endocrinology and Metabolism 81 1454–1459.
Chappell PE, Schneider JS, Kim P, XuM, Lydon JP, O’Malley BW& Levine JE
1999 Absence of gonadotropin surges and gonadotropin-releasing hormone
self-priming in ovariectomized (OVX), estrogen (E2)-treated, progesterone
receptor knockout (PRKO) mice. Endocrinology 140 3653–3658.
Fink G 1988 Gonadotropin secretion and its control. In The Physiology of
Reproduction, pp 1349–1377. Eds EKnobil & JNeill. NewYork:Raven Press.
Fink G 1995 The self-priming effect of LHRH: A unique servomechanism
and possible cellular model for memory. Frontiers in Neuroendocrinology 16
183–190.
Fink G 2000 Neuroendocrine regulation of pituitary function. In
Neuroendocrinology in Physiology and Medicine, pp 107–133. Eds PM Conn &
ME Freeman. Totowa, NJ: Humana Press Inc..
Fox SR, Harlan RE, Shievers BD & Pfaff DW 1990 Chemical
characterization of neuroendocrine targets for progesterone in the female
rat brain and pituitary. Neuroendocrinology 51 276–283.
Greenwood FC, Hunter WM & Glover JS 1963 The preparation of 131I-
labeled human growth hormone of high specific radioactivity. Biochemical
Journal 89 114–123.
Harms PG & Ojeda SR 1974 A rapid and simple procedure for chronic
cannulation of the jugular vein. Journal of Applied Physiology 3 391–392.
Harrington WR, Sheng S, Barnett DH, Petz LN, Katzenellenbogen JA &
Katzenellenbogen BS 2003 Activities of estrogen receptor alpha- and beta-
selective ligands at diverse estrogen responsive gene sites mediating transactiva-
tion or transrepression.Molecular and Cellular Endocrinology 206 13–22.
Iwata J & Nishikaze O 1979 New micro-turbidimetric method for
determination of protein in cerebrospinal fluid and urine. Clinical Chemistry
25 1317–1319.
Kelly MJ & Levin ER 2001 Rapid actions of plasma membrane estrogen
receptors. Trends in Endocrinology and Metabolism 12 152–156.
Kuiper GC, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S &
Gustafsson JA 1997 Comparison of the ligand binding specificity and
transcript tissue distribution of estrogen receptors a and b. Endocrinology 138
863–870.
Legan SJ & Tsai H-W 2003 Oestrogen receptor-a and -b immunoreactivity
in gonadotropin-releasing hormone neurones after ovariectomy and
chronic exposure to oestradiol. Journal of Neuroendocrinology 15 1164–1179.
Levin ER 2001 Cell localization, physiology, and nongenomic actions of
estrogen receptors. Journal of Applied Physiology 91 1860–1867.
Levin ER 2005 Integration of the extranuclear and nuclear actions of
estrogen. Molecular Endocrinology 19 1951–1959.
Levine JE 1997 New concepts of the neuroendocrine regulation of
gonadotropin surges in rats. Biology of Reproduction 56 293–302.
Levine JE, Chappell PE, Schneider JS, Sleiter NC & Szabo M 2001
Progesterone receptors as neuroendocrine integrators. Frontiers in Neuro-
endocrinology 22 69–106.
Lindzey J, Layes FL, Yates MM, Couse JF & Korach KS 2006 The bi-modal
effects of estradiol on gonadotropin synthesis and secretion in female mice
are dependent on estrogen receptor-a. Journal of Endocrinology 191 309–317.
McDonnell DP 1999 The molecular pharmacology of SERMs. Trends in
Endocrinology and Metabolism 10 301–311.
McDonnell DP 2003 Mining the complexities of the estrogen signaling
pathway for novel therapeutics. Endocrinology 144 4237–4240.
McDonnell DP, Connor CE, Wijayaratne A, Chang Ch-Y & Norris JD 2002
Definition of the molecular and cellular mechanism underlying the tissue-
selective agonist/antagonist activities of selective estrogen receptor
modulators. Recent Progress in Hormone Research 57 295–316.
Meyers MJ, Sun J, Carlson KE, Marriner A, Katzenellenbogen BS &
Katzenellenbogen JA 2001 Estrogen receptor-b potency-selective ligands:
structure-activity relationship studies of diarylpropionitriles and their
acetylene and polar analogues. Journal of Medicinal Chemistry 44 4230–4251.
www.endocrinology-journals.org
ER isoforms and sites modulate LH secretion . J C GARRIDO-GRACIA, A GORDON and others 119
Mitchner NA, Garlic C & Ben-Jonathan N 1998 Cellular distribution and
gene regulation of estrogen receptors a and b in the rat pituitary gland.
Endocrinology 139 3976–3983.
Neef G, Beier S, Elger W, Henderson D &Wiechert R 1984 New steroid with
antiprogestational and antiglucocorticoid activities. Steroids 44 349–372.
Pelletier G, Li S, Phaneuf D, Martel C & Labrie F 2003 Morphological studies
of prolactin-secreting cells in estrogen receptor a and estrogen receptor bknockout mice. Neuroendocrinology 77 324–333.
Razandi M, Pedram A, Greene GL & Levin ER 1999 Cell membrane and
nuclear estrogen receptors (ERs) originate from a single transcript: studies
of ERa and ERb expressed in Chinese hamster ovary cells. Molecular
Endocrinology 13 307–319.
Sanchez-Criado JE, Galiot F, Bellido C, Gonzalez D & Tebar M 1993
Hypothalamus-pituitary-ovarian axis in cyclic rats lacking progesterone
actions. Biology of Reproduction 48 916–925.
Sanchez-Criado JE, Guelmes O, Bellido C, Gonzalez M, Hernandez G,
Aguilar R, Garrido-Gracia JC, Bello AR & Alonso R 2002 Tamoxifen but
not other selective estrogen receptor modulators antagonizes estrogen
actions on luteinizing hormone secretion while inducing gonadotropin-
releasing hormone self-priming in the rat. Neuroendocrinology 76 203–213.
Sanchez-Criado JE, Martın de las Mulas J, Bellido C, Tena-Sempere M, Aguilar
R & Blanco A 2004 Biological role of pituitary estrogen receptors ERa and
ERbonprogesterone receptor expression and action and ongonadotropin andprolactin secretion in the rat.Neuroendocrinology 79 247–258.
Sanchez-Criado JE, Martın de las Mulas J, Bellido C, Aguilar R & Garrido-
Gracia JC 2005a Gonadotroph oestrogen receptor-a and -b and
progesterone receptor immunoreactivity after ovariectomy and exposure to
oestradiol benzoate, tamoxifen or raloxifene in the rat: correlation with LH
secretion. Journal of Endocrinology 184 59–68.
Sanchez-Criado JE, Bellido C, Aguilar R & Garrido-Gracia JC 2005b A
paradoxical inhibitory effect of oestradiol-17b on GnRH self-priming in
pituitaries from tamoxifen-treated rats. Journal of Endocrinology 186 43–49.
Sanchez-Criado JE, Martın de las Mulas J, Bellido C, Navarro VM, Aguilar R,
Garrido-Gracia JC, Malagon MM, Tena-Sempere M & Blanco A 2006a
Gonadotropin secreting cells in ovariectomized rats treated with different
oestrogen receptor (ER) ligands: a modulatory role for ERb in the
gonadotrope? Journal of Endocrinology 188 167–177.
Sanchez-Criado JE, Garrido-Gracia JC, Bellido C, Aguilar R, Guelmes P,
Abreu P, Alonso R, Barranco I, Millan Y & Martın de las Mulas J 2006b
Oestradiol-17b inhibits tamoxifen-induced LHRH self-priming blocking
hormone-dependent and ligand-independent activation of the gonadotrope
progesterone receptor in the rat. Journal of Endocrinology 190 73–84.
Schmidt BMW, Gerdes D, Feuring M, Falkenstein E, Christ M &Wehling M
2000 Rapid, nongenomic steroid actions: a new age? Frontiers in
Neuroendocrinology 21 57–94.
Schuiling GA, Valkhof N & Koiter TR 1999 FSH inhibits the augmentation
by oestradiol of the pituitary responsiveness to GnRH in the female rat.
Human Reproduction 14 21–26.
www.endocrinology-journals.org
Schwartz NB 2000 Neuroendocrine regulation of reproductive cyclicity.
InNeuroendocrinology in Physiology and Medicine, pp 135–145. Eds PM Conn
& ME Freeman. Totowa, NJ: Humana Press Inc.
Simoncini T & Genazzani AR 2003 Non-genomic actions of sex steroid
hormones. European Journal of Endocrinology 148 281–292.
Smith CL & O’Malley BW 2004 Coregulator function: a key to under-
standing tissue specificity of selective receptor modulators. Endocrine
Reviews 25 45–71.
Stauffer SR, Coletta CJ, Tedesco R, Nishiguchi G, Carlson K, Sun J,
Katzenellenbogen BS & Katzenellenbogen JA 2000 Pyrazole ligands:
structure-affinity/activity relationships and estrogen receptor-a-selective
agonist. Journal of Medicinal Chemistry 43 4934–4947.
Sun J, Huang YR, Harrington WR, Sheng S, Katzenellenbogen JA &
Katzenellenbogen BS 2002 Antagonists selective for estrogen receptor a.
Endocrinology 143 941–947.
Toran-Allerand CD 2004 Minireview: a pletora of estrogen receptors in the
brain: where will it end? Endocrinology 145 1069–1074.
Toran-Allerand CD, Singh M & Setalo G 1999 Novel mechanism of estrogen
action in the brain: new players in an old story. Frontiers in Neuroendocrinology
20 97–121.
Turgeon JL & Waring DW 1991 The timing of progesterone-induced
ribonucleic acid and protein synthesis for augmentation of luteinizing
hormone secretion. Endocrinology 129 3234–3239.
Turgeon JL & Waring DW 1994 Activation of the progesterone receptor by
the gonadotropin-releasing hormone self priming signaling pathway.
Molecular Endocrinology 8 860–869.
Tzuckerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB,
Pike J&McDonnellDP1994Humanestrogen receptor transcriptional capacity
is determined by both cellular and promoter context and mediated by two
functionally distinct intramolecular regions.Molecular Endocrinology 8 21–30.
Vaillant C, Chesnel F, Schausi D, Tiffoche C & Thieulant ML 2002 Expression
of estrogen receptor subtypes in rat pituitary gland during pregnancy and
lactation. Endocrinology 134 4249–4258.
Waring DW & Turgeon JL 1980 Luteinizing hormone-releasing hormone-
induced luteinizing hormone secretion in vitro: cyclic changes in
responsiveness and self-priming. Endocrinology 106 1430–1436.
Waring DW&Turgeon JL 1992 A pathway for luteinizing hormone-releasing
hormone self-potentiation: cross-talk with the progesterone receptor.
Endocrinology 130 3275–3282.
Received in final form 15 January 2007Accepted 17 January 2007Made available online as an Accepted Preprint25 January 2007
Journal of Endocrinology (2007) 193, 107–119